InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.14
(
0.00%
)
Bitcoin
63,361.56
(
0.25%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 243

Friday, 07/13/2018 12:42:37 PM

Friday, July 13, 2018 12:42:37 PM

Post# of 438
ISR the worldwide market for Cesium-131 radiation therapies is gradually improving and this company has cornered it.

Presently, the great majority of revs come from selling brachytherapy seeds for prostrate cancer patients.

This week, FDA approved their collagen-based Cesium-131 carrier technology for recurrent brain tumors.

In the most recent Q, revs were up 23% YOY.

With this financing, cash runway now extends into 2020.

The next time this stock bases, it will likely be a good investment.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up